(Alliance News) - Imaging Biometrics Ltd shares fell on Friday, after it said it will no longer proceed with an intended phase 2 trial of gallium maltolate. Read More
(Alliance News) - Imaging Biometrics Ltd on Wednesday said it has expanded its global distribution agreement with GE Healthcare Technologies Inc to widen access to two of its advanced neuroimaging products, FTB Express and QSMetric. Read More
(Alliance News) - Imaging Biometrics Ltd on Thursday noted the use of its Functional Tumor Burden mapping technology in a glioblastoma clinical trial at Cooper University's MD Anderson Cancer Center. Read More
(Alliance News) - Imaging Biometrics Ltd on Monday said it has successfully completed the phase one trial evaluating oral gallium maltolate for the treatment of recurrent or relapsed glioblastoma. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Imaging Biometrics Ltd on Friday said it has entered a research and commercial partnership with personalised cancer medicine firm Vivan Therapeutics to explore potential anti-cancer uses of gallium maltolate. Read More
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Imaging Biometrics Ltd on Wednesday said its first-half loss narrowed, helped by lower costs, despite a drop in revenue due to the absence of a prior-year grant. Read More